Azee, Inc.

Genomics company completes agreement for small molecule technology

Published in Pharma Investments, Ventures and Law Weekly, August 7th, 2005

Azee, Inc., developer of DNA-binding drugs called small molecule anti-genomic therapeutics (SMATs), announced that it has completed a license and asset purchase agreement with Oscient Pharmaceuticals Corporation (Waltham, Massachusetts) to secure rights to certain intellectual property relating to the SMAT technology.

In exchange for the license rights, Azee agreed to pay a royalty on products derived from the licensed technology and issued shares of common stock. In addition, Azee will have the right to acquire the licensed technology upon the later achievement of certain agreed upon milestones and payment of additional consideration.

"We are very...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly

Source: Pharma Investments, Ventures and Law Weekly (2005-08-07)

More Articles from Pharma Investments, Ventures and Law Weekly

Access Pharmaceuticals, Inc.
American Stock Exchange accepts pharma firm's plan for compliance
Adventrx Pharmaceuticals, Inc.
Pharmaceutical company joins the new Russell Microcap index
Alpharma, Inc.
Pharma company declares regular quarterly cash dividend
Avesthagen
Indian biotech firm among key investors in U.K.
Bausch & Lomb
Ophthalmology firm to acquire Chinese ophthalmic pharmaceuticals company
Bavarian Nordic A/S
U.S. patent granted for modified virus ankara
More from this issue of Pharma Investments, Ventures and Law Weekly

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry